Therakind aims to increase the availability of safe and effective authorised speciality medicines for children and other less-considered patient groups. Therakind look for areas of unmet medical need in these patient groups and then create, develop and improve medicines to help meet these needs.

Therakind has already successfully brought three speciality medicines to market:

• Buccolam^® – midazolam oromucosal solution for children from three months to 18 years, marketed by Shire
• Ayendi^® – intranasal diamorphine for children aged 2-15 years, marketed by Wockhardt
• Jylamvo^® – methotrexate oral solution 2 mg/ml for children ≥ 3 years old and adults, marketed by Therakind

An extensive pipeline of products is under development. Therakind also provides some consultancy in the area of paediatric development.

Read more on our Spotlight Section.